Keith Mallinson

Keith Mallinson has more than 25 years of experience in the telecommunications industry: as a research analyst, consultant and testifying expert witness. Complementing his industry focus, he has a broad skill set including technologies, market analysis, regulation, economics and finance. He has published numerous articles and speaks publicly at major industry events on a wide variety of topics including market developments and competition in next generation mobile network technologies, semiconductors, patents and licensing.

Prior to founding expert consulting firm WiseHarbor in 2006, Mallinson led industry analyst firm Yankee Group’s global Wireless/Mobile research and consulting team as an Executive Vice President, based in Boston from 2000. Until then, he had overall responsibility for the firm’s European division, as Managing Director from 1995. Prior to that he was the European Research Director.

He started his career in military communications design, project management and commercial systems engineering at the UK Ministry of Defence. He also worked as an engineer at an electronic security systems company. For several years he was a director at a seed capital investment firm specializing in ICT and biotechnology.

When AI Helps Generate Inventions, Who Is the Inventor?

By Andrei Iancu and Rama Elluru This commentary from the CSIS-SCSP Task Force on IP in the AI Era was originally published in the Special Competitive Studies Project’s Substack on February 15, 2024. With roots in the U.S. constitution, patent rights provide an exclusive property right in new inventions like drugs,
Read More

Standard Essential Patents and European Economic Security

By Kirti Gupta and Chris Borges On April 27, 2023, the European Commission published a draft proposal on standard essential patents (SEPs) seeking to address the perceived lack of transparency and predictability in the licensing of SEPs. The commission proposes the creation of a competence center within the European Union Intellectual
Read More

Proposed Federal Use of March-in Rights Would Weaken American Innovation

By Sujai Shivakumar and Thomas Howell   The Biden administration is considering exercising something called “march-in rights” as a policy prescription to curb drug prices. But as with any prescription, there is a need to weigh efficacy against the side-effects. In this case, there is evidence that the vast majority of
Read More